JPRN-UMIN000049022招募中Unknown
Efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring rare driver oncogene - Efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring rare driver oncogene
orth East Japan Study Group0 个研究点目标入组 870 人开始时间: 2022年9月26日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 870
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients who are judged by the principal investigator or sub-investigator to be inappropriate for participation in this study. (2) Patients who had no driver mutation/translocation or EGFR mutation only.
研究者
相似试验
已完成
不适用
Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinomaPulmonary sarcomatoid carcinomaJPRN-UMIN000046002Kobe University124
已完成
不适用
The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutantsung cancerJPRN-UMIN000040789Yokohama City University
已完成
不适用
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational studyon-small cell lung cancer other than adenocarcinoma or squamous cell carcinomaJPRN-UMIN000037777Hamamatsu University School of Medicine60
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
进行中（未招募）
1 期
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.EUCTR2021-000058-24-NLErasmus MC Cancer Institute390